1
|
Su H, Wang M, Pang X, Guan F, Li X, Cheng Y. When Glycosylation Meets Blood Cells: A Glance of the Aberrant Glycosylation in Hematological Malignancies. Rev Physiol Biochem Pharmacol 2021; 180:85-117. [PMID: 34031738 DOI: 10.1007/112_2021_60] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Among neoplasia-associated epigenetic alterations, changes in cellular glycosylation have recently received attention as a key component of hematological malignancy progression. Alterations in glycosylation appear to not only directly impact cell growth and survival, but also alter the adhesion of tumor cells and their interactions with the microenvironment, facilitating cancer-induced immunomodulation and eventual metastasis. Changes in glycosylation arise from altered expression of glycosyltransferases, enzymes that catalyze the transfer of saccharide moieties to a wide range of acceptor substrates, such as proteins, lipids, and other saccharides in the endoplasmic reticulum (ER) and Golgi apparatus. Novel glycan structures in hematological malignancies represent new targets for the diagnosis and treatment of blood diseases. This review summarizes studies of the aberrant expression of glycans commonly found in hematological malignancies and their potential mechanisms and defines the specific roles of glycans as drivers or passengers in the development of hematological malignancies.
Collapse
Affiliation(s)
- Huining Su
- Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China
| | - Mimi Wang
- Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China
| | - Xingchen Pang
- Key Laboratory of Resource Biology and Biotechnology Western China, College of Life Science, Northwest University, Xi'an, China
| | - Feng Guan
- Key Laboratory of Resource Biology and Biotechnology Western China, College of Life Science, Northwest University, Xi'an, China
| | - Xiang Li
- Key Laboratory of Resource Biology and Biotechnology Western China, College of Life Science, Northwest University, Xi'an, China.
| | - Ying Cheng
- Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China.
| |
Collapse
|
2
|
Abstract
The interferons (IFNs) and their receptors represent a subset of the class 2 alpha-helical cytokines that have been in chordates for millions of years. This brief review focuses on the discovery and purification of interferons, cloning of human IFN-alpha and IFN-beta, interferon receptors, activities and therapeutic uses of interferons, and the side effects of interferons.
Collapse
Affiliation(s)
- Sidney Pestka
- Department of Molecular Genetics, Microbiology, and Immunology, Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA.
| |
Collapse
|
3
|
Voutsadakis IA. Interferon-alpha and the pathogenesis of myeloproliferative disorders. Med Oncol 2000; 17:249-57. [PMID: 11114703 DOI: 10.1007/bf02782189] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2000] [Accepted: 04/13/2000] [Indexed: 11/29/2022]
Abstract
Interferon-alpha (IFN-alpha), a molecule with multiple biological actions, is widely used in the treatment of chronic myelogenous leukemia (CML) and the other myeloproliferative disorders. This glycoprotein belonging to the type I subfamily of interferons has been recombinantly manufactured and has been approved for the biotherapy of CML, now becoming the first line of treatment for CML patients in chronic phase who are not candidates for allogeneic hematopoietic stem cell or bone marrowtransplantation. Interferon-alpha action involves binding to its cell membrane receptor and initiation of an intracellular signal transduction cascade. Two major pathways mediate the biologic actions of IFN-alpha. The JAK-STAT pathway leads to phosphorylation and activation of STAT 1 and STAT 2 molecules and transcription of genes like p21 and caspase-1 resulting in cycle arrest and apoptosis. The PKR (protein kinase dsRNA-induced) kinase phosphorylates and inhibits the eukaryotic initiator of translation eIF-2alpha leading again to apoptosis. The PKR kinase cascade also leads to activation of the transcription factor NF-kappaB. The relevance of this activation is unclearand it is possiblethat NF-kappaB has not had the opportunity to transcribe its target genes as it is a substrate of effector caspases and is maybe cleaved by them before exerting any transcription activity. Through the JAK-STAT and the PKR kinase pathways IFN-alpha is able to modify the proliferative and antiapoptotic actions of the constitutively activated kinase bcr-abl, the product of the t(9;22) translocation present in CML, and has therapeutic effects in this disease.
Collapse
MESH Headings
- Antineoplastic Agents/immunology
- Antineoplastic Agents/pharmacology
- Apoptosis/drug effects
- Cell Cycle/drug effects
- Humans
- Interferon-alpha/immunology
- Interferon-alpha/pharmacology
- Janus Kinase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/physiopathology
- Myeloproliferative Disorders/drug therapy
- Myeloproliferative Disorders/etiology
- Myeloproliferative Disorders/immunology
- Protein-Tyrosine Kinases/metabolism
- Proto-Oncogene Proteins
- Transcription, Genetic
Collapse
Affiliation(s)
- I A Voutsadakis
- Department of Medicine, Mount Sinai Hospital and Mount Sinai School of Medicine, New York, NY 10029, USA.
| |
Collapse
|
4
|
Abstract
Interferon (IFN) was approved by the U.S. Food and Drug Administration on June 5, 1986. As the first biotherapeutic approved, IFN-alpha paved the way for development of many other cytokines and growth factors. Nevertheless, we have just touched the surface of understanding the multitude of human IFNs. This paper reviews the history of the purification of human leukocyte IFN and key aspects of our current state of knowledge of human interferon alpha genes, proteins, and receptors.
Collapse
Affiliation(s)
- S Pestka
- Department of Molecular Genetics and Microbiology, Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854-5635, USA.
| |
Collapse
|
5
|
Viscomi GC, Antonelli G, Bruno C, Scapol L, Malavasi F, Funaro A, Simeoni E, Pestka S, De Pisa F, Dianzani F. Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN-alpha by monoclonal antibodies. J Interferon Cytokine Res 1999; 19:319-26. [PMID: 10334382 DOI: 10.1089/107999099314018] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
To gain more insight into similarities of different interferon-alpha (IFN-alpha) species, we evaluated neutralization and immunoactivity of a variety of IFN preparations with various monoclonal antibodies (IFN-alpha mAb). Nine IFN-alpha mAb obtained through immunization with recombinant IFN-alpha (rmAb), lymphoblastoid IFN-alpha (LY mAb), and leukocyte IFN-alpha (LE mAb) were tested. The IFN-alpha mAb were evaluated for their ability to neutralize the antiviral activity of 11 recombinant IFN-alpha subtypes, two recombinant IFN-alpha hybrids, and lymphoblastoid and leukocyte IFN-alpha preparations. The same IFN-alpha mAb were also used in immunoblotting, and some of them were used in immunoaffinity chromatography. The results of the neutralization assay reveal that the IFN-alpha mAb significantly differ in their ability to neutralize the individual IFN-alpha species. Interestingly, none of the IFN-alpha mAb was able to neutralize all the IFN-alpha species. In particular, rmAb were unable to neutralize LE-IFN-alpha or LY-IFN-alpha, whereas LE mAb and LY mAb efficiently neutralized rIFN-alpha2. In some cases, the epitopes to which IFN-alpha mAb are directed were identified through the use of synthetic fragments of IFN-alpha2 or by evaluating the selectivity in binding to IFN-alpha subtypes.
Collapse
Affiliation(s)
- G C Viscomi
- Biotechnology Department, Alfa Wassermann, Bologna, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Ahmed CM, Sugarman BJ, Johnson DE, Bookstein RE, Saha DP, Nagabhushan TL, Wills KN. In vivo tumor suppression by adenovirus-mediated interferon alpha2b gene delivery. Hum Gene Ther 1999; 10:77-84. [PMID: 10022532 DOI: 10.1089/10430349950019200] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
A replication-deficient adenovirus encoding human interferon alpha2b, driven by the human cytomegalovirus (CMV) promoter, was constructed and characterized. This construct was used to infect human cells derived from different types of cancer. The production of protein and its secretion into the culture medium were tested by Western blotting and immunoassay. Inhibition of cell proliferation and antiviral activity, two of the most important biological activities of interferon, were observed with this construct. PC-3 cells, derived from human prostatic cancer, or Hep3B cells, derived from human hepatocellular carcinoma, were injected subcutaneously to generate and establish in vivo tumors in athymic nude mice. Intratumoral injection with the recombinant adenovirus expressing interferon alpha2b resulted in complete regression of tumor growth. Our results demonstrate that interferon gene delivery using recombinant adenoviral vectors may be a useful approach to treat a variety of cancers.
Collapse
Affiliation(s)
- C M Ahmed
- Canji, Inc., San Diego, CA 92121, USA
| | | | | | | | | | | | | |
Collapse
|
7
|
Walter MR, Bordens R, Nagabhushan TL, Williams BR, Herberman RB, Dinarello CA, Borden EC, Trotta PP, Pestka S, Pfeffer LM. Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon. Cancer Biother Radiopharm 1998; 13:143-54. [PMID: 10850350 DOI: 10.1089/cbr.1998.13.143] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Recombinant alfa interferons (IFN-alpha s) are approved worldwide for the treatment of a variety of cancers and diseases of virologic origin. A series of recent advances in the molecular characterization of recombinant IFN-alpha s have allowed the determination of the three-dimensional IFN-alpha 2b structure by high-resolution x-ray crystallography. We review here recent developments in our understanding of the molecular and physicochemical properties of recombinant IFN-alpha, including our current state of knowledge of the IFN-alpha gene family and the multiple species of human leukocyte IFN. Based on the reported three-dimensional structure of IFN-alpha 2b, we propose a molecular model for the IFN-alpha 2b receptor complex and predict models for the naturally occurring subtypes IFN-alpha 1 and IFN-alpha 8, as well as the synthetic, non-naturally occurring consensus IFN. Such models provide molecular insights into the mechanism of action of IFN-alpha.
Collapse
Affiliation(s)
- M R Walter
- Department of Microbiology, University of Alabama at Birmingham 35294-0005, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Zoon K, Miller D, Bekisz J, zur Nedden D, Enterline J, Nguyen N, Hu R. Purification and characterization of multiple components of human lymphoblastoid interferon-alpha. J Biol Chem 1992. [DOI: 10.1016/s0021-9258(18)42167-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
9
|
Adolf GR, Kalsner I, Ahorn H, Maurer-Fogy I, Cantell K. Natural human interferon-alpha 2 is O-glycosylated. Biochem J 1991; 276 ( Pt 2):511-8. [PMID: 2049076 PMCID: PMC1151121 DOI: 10.1042/bj2760511] [Citation(s) in RCA: 62] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Natural human interferon alpha 2 (IFN-alpha 2) was isolated from a preparation of partially purified human leucocyte IFN by monoclonal-antibody immunoaffinity chromatography. The purified protein had a specific activity of 1.5 x 10(8) i.u./mg; it was estimated to constitute 10-20% of the total antiviral activity of leucocyte IFN. N-Terminal amino-acid-sequence analysis identified the subspecies IFN-alpha 2b and/or IFN-alpha 2c, whereas IFN-alpha 2a was not detectable. The structure of natural IFN-alpha 2 was found to differ from that of its recombinant (Escherichia coli-derived) equivalent. First, reverse-phase h.p.l.c. showed that natural IFN-alpha 2 was significantly more hydrophilic then expected. Secondly, the apparent molecular mass of the natural protein determined by SDS/PAGE was higher than that of recombinant IFN-alpha 2; incubation under mild alkaline conditions known to eliminate O-linked carbohydrates resulted in a reduction of the apparent molecular mass to that of the recombinant protein. On sequence analysis of proteolytic peptides, Thr-106 was found to be modified. These results suggested that Thr-106 of natural IFN-alpha 2 carries O-linked carbohydrates. Reverse-phase h.p.l.c. as well as SDS/PAGE of natural IFN-alpha 2 showed that glycosylation is heterogeneous. For characterization of the carbohydrate moieties, the protein was treated with neuraminidase and/or O-glycanase and analysed by gel electrophoresis; in addition, glycopeptides obtained by proteinase digestion and separated by h.p.l.c. were characterized by sequence analysis and m.s. Further information on the composition of the glycans was obtained by monosaccharide analysis. The results indicate that natural IFN-alpha 2 contains the disaccharide galactosyl-N-acetylgalactosamine (Gal-GalNAc) linked to Thr-106. In part of the molecules, this core carbohydrate carries (alpha-)N-acetylneuraminic acid, whereas a disaccharide, probably N-acetyl-lactosamine, is bound to Gal-GalNAc in another proportion of the protein. Further glycosylation isomers are present in small amounts. As IFN-alpha 2 is the only IFN-alpha species with a threonine residue at position 106, it may represent the only O-glycosylated human IFN-alpha protein.
Collapse
Affiliation(s)
- G R Adolf
- Ernst-Boehringer-Institut für Arzneimittelforschung, Bender + Co Ges mbH, Vienna, Austria
| | | | | | | | | |
Collapse
|
10
|
Baumbach GA, Duby RT, Godkin JD. N-glycosylated and unglycosylated forms of caprine trophoblast protein-1 are secreted by preimplantation goat conceptuses. Biochem Biophys Res Commun 1990; 172:16-21. [PMID: 2222465 DOI: 10.1016/s0006-291x(05)80166-4] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Goat conceptuses secrete caprine trophoblast protein-1 (cTP-1) which is related antigenically to the abundant embryonic interferon-alpha II of sheep and cattle. Antiserum to ovine and bovine TP-1s immunoprecipitated three molecular weight classes (23,000, 21,000 and 17,000, each with two isotypes) of cTP-1 from goat conceptus culture medium. Cultures which contained tunicamycin resulted in a shift in the Mr = 23,000 and Mr = 21,000 forms to a Mr of 17,000. The Mr = 23,000 and 21,000 forms, but not the Mr = 17,000 form, bound to Concanaval in A-Sepharose and were eluted under conditions selective for glycoproteins bearing complex-type oligosaccharide(s). Thus cTP-1 is a mixture of glycosylated and unglycosylated polypeptides.
Collapse
Affiliation(s)
- G A Baumbach
- Department of Animal Science, University of Tennessee, Knoxville 39701-1071
| | | | | |
Collapse
|
11
|
Abstract
Recent applications of recombinant DNA techniques have enabled the cloning of several interesting human genes, leading to the production of rare biologicals in abundant quantities. We review here the discovery, early characterization, cloning, and expression of Interferon Alfa-2B (IFN alpha-2b or Intron A) as a therapeutic at Schering-Plough Research. IFN alpha-2a is marketed by Hoffman LaRoche under the trade name Roferon. The studies on the expression, purification, biology, and clinical aspects of this interferon offer a plethora of information on one of the earliest recombinant DNA based drugs to reach the market place.
Collapse
Affiliation(s)
- E Baron
- Georgetown University School of Medicine, Washington, D.C
| | | |
Collapse
|
12
|
Abstract
Natural porcine interferons (PoIFNs) were obtained from: adherent peripheral blood leukocytes induced with Newcastle disease virus (NDV) (IFN-alpha), kidney fibroblasts induced with poly(I:C) (IFN-beta) and whole blood leukocytes induced with phytohemagglutinin (IFN-gamma). PoIFN-alpha was active in porcine, bovine, human, and murine cells. It was sensitive to anti-human IFN-alpha antiserum. Analyzed by SDS-polyacrylamide gel electrophoresis and by gel filtration, the molecular weight of the main fraction of PoIFN-alpha was between 25,200 and 28,700. PoIFN-beta and a small fraction of PoIFN-alpha were bound to concanavalin A which suggests that they are glycoproteins. PoIFN-beta and PoIFN-gamma were active only in porcine and bovine, and porcine cells, respectively. Physicochemical properties of porcine IFNs resembled those of human IFNs. PoIFN-alpha or PoIFN-beta and PoIFN-gamma acted synergistically in the antiviral assays. Thus, the porcine IFN system appears to be similar to the system in the human and in murine species, being serologically related to the former.
Collapse
Affiliation(s)
- E Piasecki
- Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw
| |
Collapse
|
13
|
Affiliation(s)
- V Bocci
- Institute of General Physiology, University of Siena, Italy
| |
Collapse
|
14
|
Goren T, Fischer DG, Rubinstein M. Human monocytes and lymphocytes produce different mixtures of alpha-interferon subtypes. JOURNAL OF INTERFERON RESEARCH 1986; 6:323-9. [PMID: 3772176 DOI: 10.1089/jir.1986.6.323] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
alpha-Interferon (IFN-alpha) was produced by either peripheral blood lymphocytes or by monocytes and purified by an anti-IFN-alpha affinity column. When these preparations were analyzed by reversed-phase HPLC, a difference in the distribution of IFN-alpha subtypes from the two cell types was found. While the two major subtypes of IFN from induced lymphocytes had apparent molecular weights of 20K and 21K, monocytes produce an additional subtype of molecular weight 26K in large quantities (50%). This subtype had greater activity on human cells than on bovine cells in comparison to other IFN-alpha subtypes.
Collapse
|
15
|
Abstract
Methods that modify the carbohydrate and peptide portions of human and murine interferons have been described. Such work has helped considerably in our understanding of these fascinating substances. The most powerful of the methods relies on gene manipulation: it has already led, and will lead in the future, to further species with altered biological activities. Some of them may prove clinically advantageous, but one will have to be aware of the fact that some of these "unnatural" interferons could lead to immunological complications.
Collapse
|
16
|
Abstract
Early studies on the mode of action of interferons have indicated that a receptor system on the cell surface is involved in its action. The first direct evidence to a high-affinity binding site was found only after pure interferon was available. Two different receptors, one specific for interferons-alpha and beta, and the other for interferon-gamma were recognized. A correlation between affinity to the receptor and specific activity was established. Cross-linked complexes of labeled interferons with their receptors were visualized on gel electrophoresis and even partially purified. Internalization of interferons after binding to the receptor was reported. The role of gangliosides as helpers of interferon binding was recently investigated. Fragments of interferons which still retained binding capacity were described and helped in elucidating the binding site on the interferon molecule.
Collapse
|
17
|
|
18
|
|